ZOLL’s PocketCPR for iPhone Training App Debuts to Over 17,000 Downloads During AHA
Medtronic, Inc. received today an International Business Leadership Award from the Greater Miami Chamber of Commerce in recognition for its significant impact on the economy of the state of Florida in the Education & Training category.
Non-Invasive Monitoring Systems, Inc. [NIMS] (OTCBB:NIMU) announced that the Nogawa Patent Office in Japan issued Patent number 4391595 to NIMS on October 16, 2009. This patent, entitled “Reciprocating Movement Platform for Shifting Subject To and Fro In Headwards-Footwards Direction,” relates to the comprehensively researched technology underlying NIMS’ Exer-Rest acceleration therapeutic platform. This patent expires on March 18, 2018.
Asuragen, Inc., a leader in molecular diagnostic development, announced today that it will present at the Association for Molecular Pathology (AMP) 15th Annual Meeting, November 19-22, 2009 in Kissimmee, FL. Eight posters and a podium talk will be presented highlighting Asuragen’s development efforts in the areas of oncology, genetic testing, microRNA and laboratory standards.
ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx’s compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida. The primary efficacy and safety results from PASCAL were announced in early 2009, demonstrating that budiodarone significantly reduces atrial fibrillation (AF) burden, or the time spent in AF, in patients suffering from paroxysmal AF. The details reviewed today focused on budiodarone’s rapid on-set of action, with a significant reduction in patients’ AF burden occurring within the first thirty days of treatment in two of three doses tested. In addition, the effect of budiodarone was sustained over the course of three months of treatment. Budiodarone is a novel oral antiarrythmic therapy modeled on the efficacy of amiodarone, the gold standard treatment for atrial fibrillation.
$3 Million Chesapeake Algae Project (ChAP) Researching Commercial Viability of Algae Biofuels
SafeStitch Medical, Inc. (OTCBB:SFES) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its AMID StaplerTM in the U.S. with the intended use in general surgery procedures for fixation of mesh, in the repair of hernia defects and in other surgical specialties for the approximation of tissues, including skin. The AMID Stapler™ is the first surgical stapler designed specifically for use in inguinal hernia repairs using the Lichtenstein method, in which mesh is implanted to reinforce the groin floor. The Company has also applied for clearance to market the AMID StaplerTM in the European Economic Community and other areas outside of the U.S.
Celladon Corporation, developing therapies for the treatment of heart failure, today announced upcoming data presentations at the American Heart Association (AHA) Scientific Sessions, November 14-18, 2009, Orlando, Florida.
Results from HEAAL Study Presented as Late-Breaker at American Heart Association Scientific Sessions 2009
ZOLL Technology a Key Part of “Resuscitation Bundle” Improvement Report at AHA Resuscitation Science Symposium
A Florida cardiologist is using stem cell therapy to treat patients who suffer from a range of heart, lung and vascular illnesses. The results have been extraordinary.
Results Will Be Presented Today At AHA Conference in Orlando, Florida
Dyadic International, Inc. (Pink Sheets:DYAI) (“Dyadic”) today announced financial results for the third quarter ended September 30, 2009. The financial information contained in this press release should be read in conjunction with the financial statements and footnotes for the three and nine month periods ended September 30, 2009 as well as the financial statements, footnotes and independent auditors’ report for the year ended December 31, 2008 which have been posted on the Pink Sheets website at www.pinksheets.com and on Dyadic’s website at www.dyadic.com.
Revenues Exceed $2.1M
Randolph K. Geissler, Founder of Destron Fearing and Former CEO of Digital Angel Corporation, Assumes Role of Chief Executive Officer of PositiveID Animal Health
To Jointly Develop & Commercialize Patented Nutraceuticals
At the American Heart Association meeting today, Merck & Co., Inc. said it is confident in the safety and efficacy profiles of ZETIA® (ezetimibe) and VYTORIN® (ezetimibe/simvastatin), and issued the following comment in response to misinterpretation of results from a small 200-patient imaging study called ARBITER 6.
Early Results Show Preserved Heart Size in Pacemaker Patients with Normal Left Ventricles
PanGenex Corporation (Pink Sheets:PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, is pleased to announce today that two of the nation's leading interventional cardiologists, Dr. Steven Yakubov and Dr. Mark Turco, have joined the Company's Scientific Advisory Board.
Nutra Pharma has announced its intention to begin the drug registration process in Brazil and Colombia for its over-the-counter pain reliever. The company is currently marketing a similar analgesic, Cobroxin, in the United States for the treatment of mode
RSS|
My Yahoo|
Newsletters|
Widgets|
Mobile|
Alerts|
Twitter
Terms of Service| Privacy Policy| About our ads| Copyright| About The Miami Herald| About the McClatchy Company| Corrections| Contact Us| Advertise
Partners: El Nuevo Herald| Newspaper in Education| WLRN | Miami Herald News| CBS4 WFOR-TV| More
Copyright 2009 Miami Herald Media Co. All rights reserved
